98 related articles for article (PubMed ID: 28123783)
1. Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis.
Huynh DH; Boyd TA; Etzel CJ; Cox V; Kremer J; Mease P; Kavanaugh A
RMD Open; 2017; 3(1):e000395. PubMed ID: 28123783
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry.
Kavanaugh A; Lee SJ; Curtis JR; Greenberg JD; Kremer JM; Soto L; Etzel CJ; Cox V; Yoshida K; Reed GW; Solomon DH
Ann Rheum Dis; 2015 Jun; 74(6):1150-5. PubMed ID: 25471471
[TBL] [Abstract][Full Text] [Related]
3. Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry.
Mease PJ; Karki C; Liu M; Li Y; Gershenson B; Feng H; Hur P; Greenberg JD
RMD Open; 2019; 5(1):e000880. PubMed ID: 31168408
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry.
Mease PJ; Collier DH; Saunders KC; Li G; Kremer JM; Greenberg JD
RMD Open; 2015; 1(1):e000181. PubMed ID: 26819748
[TBL] [Abstract][Full Text] [Related]
5. Rebound in Measures of Disease Activity and Symptoms in Corrona Registry Patients with Psoriatic Arthritis Who Discontinue Tumor Necrosis Factor Inhibitor Therapy after Achieving Low Disease Activity.
Harrold LR; Stolshek BS; Rebello S; Collier DH; Mutebi A; Wade SW; Malley W; Greenberg JD; Etzel CJ
J Rheumatol; 2018 Jan; 45(1):78-82. PubMed ID: 28966209
[TBL] [Abstract][Full Text] [Related]
6. Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry.
Harrold LR; Stolshek BS; Rebello S; Collier DH; Mutebi A; Wade SW; Malley W; Greenberg JD; Etzel CJ
Clin Rheumatol; 2017 Apr; 36(4):895-901. PubMed ID: 28271234
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis.
Stober C; Ye W; Guruparan T; Htut E; Clunie G; Jadon D
Rheumatology (Oxford); 2018 Jan; 57(1):158-163. PubMed ID: 29077973
[TBL] [Abstract][Full Text] [Related]
8. Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor.
Ogdie A; Palmer JL; Greenberg J; Curtis JR; Harrold LR; Solomon DH; Kavanaugh A; Kremer JM; Mease PJ
J Rheumatol; 2019 May; 46(5):475-482. PubMed ID: 30647182
[TBL] [Abstract][Full Text] [Related]
9. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.
Glintborg B; Ostergaard M; Krogh NS; Andersen MD; Tarp U; Loft AG; Lindegaard HM; Holland-Fischer M; Nordin H; Jensen DV; Olsen CH; Hetland ML
Arthritis Rheum; 2013 May; 65(5):1213-23. PubMed ID: 23460467
[TBL] [Abstract][Full Text] [Related]
10. Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry.
Mease PJ; van der Heijde D; Karki C; Liu M; Park Y; Greenberg JD
Rheumatol Ther; 2018 Dec; 5(2):537-550. PubMed ID: 30353387
[TBL] [Abstract][Full Text] [Related]
11. Changes in Treatment Patterns in Patients with Psoriatic Arthritis Initiating Biologic and Nonbiologic Therapy in a Clinical Registry.
Mease PJ; Lesperance T; Liu M; Collier DH; Mason M; Deveikis S; Accortt NA
J Rheumatol; 2017 Feb; 44(2):184-192. PubMed ID: 28089969
[TBL] [Abstract][Full Text] [Related]
12. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries.
Højgaard P; Glintborg B; Kristensen LE; Gudbjornsson B; Love TJ; Dreyer L
Rheumatology (Oxford); 2016 Dec; 55(12):2191-2199. PubMed ID: 27651526
[TBL] [Abstract][Full Text] [Related]
13. Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry.
Højgaard P; Glintborg B; Hetland ML; Hansen TH; Lage-Hansen PR; Petersen MH; Holland-Fischer M; Nilsson C; Loft AG; Andersen BN; Adelsten T; Jensen J; Omerovic E; Christensen R; Tarp U; Østgård R; Dreyer L
Ann Rheum Dis; 2015 Dec; 74(12):2130-6. PubMed ID: 25063827
[TBL] [Abstract][Full Text] [Related]
14. Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS).
Pina Vegas L; Hoisnard L; Bastard L; Sbidian E; Claudepierre P
RMD Open; 2022 Dec; 8(2):. PubMed ID: 36597983
[TBL] [Abstract][Full Text] [Related]
15. Long-term effectiveness of tumour necrosis factor-α inhibitor treatment for psoriatic arthritis in the UK: a multicentre retrospective study.
Clunie G; McInnes IB; Barkham N; Marzo-Ortega H; Patel Y; Gough A; Packham J; Kyle S; Kirkham B; Sheeran T; Coope H; Bishop-Bailey A; McHugh N
Rheumatol Adv Pract; 2018; 2(2):rky042. PubMed ID: 31431979
[TBL] [Abstract][Full Text] [Related]
16. Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials.
Emamikia S; Arkema EV; Györi N; Detert J; Chatzidionysiou K; Dougados M; Burmester GR; van Vollenhoven R
RMD Open; 2016; 2(2):e000323. PubMed ID: 27651929
[TBL] [Abstract][Full Text] [Related]
17. Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis.
Song Y; Betts KA; Lu Y; Singh R; Clewell J; Griffith J
Rheumatol Ther; 2019 Jun; 6(2):285-297. PubMed ID: 31055779
[TBL] [Abstract][Full Text] [Related]
18. Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register.
Fagerli KM; Kearsley-Fleet L; Watson KD; Packham J; Contributors Group BR; Symmons DPM; Hyrich KL
RMD Open; 2018; 4(1):e000596. PubMed ID: 29479475
[TBL] [Abstract][Full Text] [Related]
19. Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis.
Chandran V; Shen H; Pollock RA; Pellett FJ; Carty A; Cook RJ; Gladman DD
J Rheumatol; 2013 Jun; 40(6):866-71. PubMed ID: 23637322
[TBL] [Abstract][Full Text] [Related]
20. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.
Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Lexberg AS; Rødevand E; Kalstad S; Mikkelsen K; Kvien TK
Ann Rheum Dis; 2014 Jan; 73(1):132-7. PubMed ID: 23291385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
